Novel Treatment Approach May Reduce Risk of Death From ICI-Related Myocarditis
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
All articles by Contributing Writer
Certain Antibiotics May Reduce the Efficacy of Certain ICIs in Cancer Patients
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Identifying and Managing Adverse Reactions to Lenvatinib and Pembrolizumab
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Factors Related to Changes in Health-Related Quality of Life Studied in Gout
Factors associated with changes in disease-specific and generic health-related quality of life were identified among patients with gout in primary care.
Tigulixostat Lowers Serum Urate Levels in Patients With Gout and Hyperuricemia
Tigulixostat vs placebo was found to be safe and effective in lowering serum urate levels among patients with gout and hyperuricemia.
Adjuvant ICI Therapy Provides DFS Benefit in Certain Patients With RCC
Certain patients with resected renal cell carcinoma may benefit from adjuvant treatment with immune checkpoint inhibitors, a meta-analysis suggests.
Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.
- Loading...
Loading...
Next post in Diabetes
Loading... 
Loading...